Emerging strategies to target RAS signaling in human cancer therapy

Emerging strategies to target RAS signaling in human cancer therapy

Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and exhibit malignant phenotypes. The mutational status of RAS correlates with the cl...

Full description

Bibliographic Details
Main Authors: Kun Chen, Yalei Zhang, Ling Qian, Peng Wang
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Hematology & Oncology
Subjects:
RAS mutations
Hotspots
Clinicopathological features
RAS-targeted therapy
Online Access:https://doi.org/10.1186/s13045-021-01127-w

Internet

https://doi.org/10.1186/s13045-021-01127-w

Similar Items